Patient advocates have long raised the question about the wisdom in using hormone therapy for extended periods of time. The introduction of intermittent scheduling of hormone therapy (ADT) has become more acceptable thanks to the questions raised by the community and the support of some oncologists who have been willing to think out of the [...]
We all know it, advanced prostate cancer not only affects the survivor, but it also affects his family. When diagnosed with advanced prostate cancer, the most common treatment is androgen deprivation therapy (ADT) which causes many side effects. These side effects include (but are not limited to) fatigue, nausea, hot flashes, pain, constipation and sexual [...]
Following failed radiation therapy (RT) the best treatment of recurrent prostate cancer remains controversial due to the lack of long-term data. Researchers reviewed the survival and establish prognostic indicators for men who received salvage cryotherapy for biopsy-proven recurrent prostate cancer. […]
The investigational drug Abiraterone, designed for the treatment of men with advanced prostate cancer who have failed chemotherapy has not yet been approved by the FDA. Because of the extraordinarily positive results that were obtained on the phase III trials (which were stopped early because of these fantastic results) the pharmaceutical manufacturer of the drug [...]
One of our biggest disputes around hormone deprivation (ADT) concerns the question of scheduling. Traditionally, ADT involved staying on the therapy drug forever. However, ADT causes significant side effects that negatively impacts both the quality of life as well as posing potential significant medical problems. Over the last five or so years there has been [...]